Uwe Platzbecker

2000–2025 年に発表

330
論文数
32,331
被引用数
87
h 指数
299
i10 指数

被引用数

Uwe Platzbecker の年別被引用数1989 年: 被引用 1 件2001 年: 被引用 1 件2002 年: 被引用 4 件2003 年: 被引用 33 件2004 年: 被引用 39 件2005 年: 被引用 43 件2006 年: 被引用 33 件2007 年: 被引用 37 件2008 年: 被引用 39 件2009 年: 被引用 43 件2010 年: 被引用 56 件2011 年: 被引用 50 件2012 年: 被引用 69 件2013 年: 被引用 115 件2014 年: 被引用 132 件2015 年: 被引用 136 件2016 年: 被引用 153 件2017 年: 被引用 165 件2018 年: 被引用 163 件2019 年: 被引用 742 件2020 年: 被引用 932 件2021 年: 被引用 1,119 件2022 年: 被引用 1,067 件2023 年: 被引用 1,189 件2024 年: 被引用 2,011 件2025 年: 被引用 1,086 件2026 年: 被引用 19 件1990〜2000 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,748 件、この内訳の 23.7%ドイツ: 引用元論文 1,154 件、この内訳の 10%イタリア: 引用元論文 851 件、この内訳の 7.3%中国: 引用元論文 829 件、この内訳の 7.2%イギリス: 引用元論文 738 件、この内訳の 6.4%フランス: 引用元論文 648 件、この内訳の 5.6%スペイン: 引用元論文 451 件、この内訳の 3.9%オランダ: 引用元論文 359 件、この内訳の 3.1%カナダ: 引用元論文 326 件、この内訳の 2.8%オーストラリア: 引用元論文 281 件、この内訳の 2.4%日本: 引用元論文 260 件、この内訳の 2.2%スイス: 引用元論文 232 件、この内訳の 2%
0%23.7%その他 23.4%

分野

  • Medicine73.9%
  • Biochemistry, Genetics and Molecular Biology18.3%
  • Immunology and Microbiology4.8%
  • Computer Science1.4%
  • Engineering0.3%
  • Neuroscience0.3%
  • その他1%

トピック

  • Acute Myeloid Leukemia Research17.7%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment6.6%
  • Hematopoietic Stem Cell Transplantation5.1%
  • Chronic Myeloid Leukemia Treatments4%
  • Acute Lymphoblastic Leukemia research3.3%
  • Retinoids in leukemia and cellular processes2.7%
  • その他60.6%

共著者

全論文

検索で開く
  1. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Joop H. Jansen, Rashmi Kanagal‐Shamanna, Hagop M. Kantarjian, Christian P. Kratz, Xiaoqiu Li, Megan S. Lim, Keith R. Loeb, Sanam Loghavi, Andrea N. Marcogliese, Soheil Meshinchi, Phillip Michaels, Kikkeri N. Naresh, Yasodha Natkunam, Reza Nejati, German Ott, Eric Padron, Keyur P. Patel, Nikhil Patkar, Jennifer Picarsic, Uwe Platzbecker, Irene Roberts, Anna Schuh, William A. Sewell, Reiner Siebert, Prashant Tembhare, Jeffrey Tyner, Srđan Verstovšek, Wei Wang, Brent L. Wood, Wenbin Xiao, Cecilia C.S. Yeung, Andreas Hochhaus - Leukemia 2022 被引用: 3,904

  2. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Akifumi Takaori‐Kondo, Takayuki Ishikawa, Shigeru Chiba, Senji Kasahara, Yasushi Miyazaki, Agnès Viale, Kety Huberman, Pierre Fenaux, Monika Beličková, Michael R. Savona, Virginia M. Klimek, Fábio Pires de Souza Santos, Jacqueline Boultwood, Ιoannis Kotsianidis, Valeria Santini, Françesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Kazuma Ohyashiki, Carlo Finelli, Maria Teresa Voso, Lee‐Yung Shih, Michaëla Fontenay, Joop H. Jansen, José Cervera, Norbert Gattermann, Benjamin L. Ebert, Rafael Bejar, Luca Malcovati, Mario Cazzola, Seishi Ogawa, Eva Hellström‐Lindberg, Elli Papaemmanuil - NEJM Evidence 2022 被引用: 813

  3. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jacqueline Boultwood, Fábio Pires de Souza Santos, Julie Schanz, Senji Kasahara, Takayuki Ishikawa, Hisashi Tsurumi, Akifumi Takaori‐Kondo, Toru Kiguchi, Chantana Polprasert, John M. Bennett, Virginia M. Klimek, Michael R. Savona, Monika Beličková, Christina Ganster, Laura Palomo, Guillermo Sanz, Lionel Adès, Matteo Giovanni Della Porta, Harold K. Elias, Alexandra Smith, Yesenia Werner, Minal Patel, Agnès Viale, Katelynd Vanness, Donna Neuberg, Kristen E. Stevenson, Kamal Menghrajani, Kelly L. Bolton, Pierre Fenaux, Andrea Pellagatti, Uwe Platzbecker, Michael Heuser, Peter Valent, Shigeru Chiba, Yasushi Miyazaki, Carlo Finelli, Maria Teresa Voso, Lee‐Yung Shih, Michaëla Fontenay, Joop H. Jansen, José Cervera, Yoshiko Atsuta, Norbert Gattermann, Benjamin L. Ebert, Rafael Bejar, Peter L. Greenberg, Mario Cazzola, Eva Hellström-Lindberg, Seishi Ogawa, Elli Papaemmanuil - Nature Medicine 2020 被引用: 636

  4. Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hartmut Link, Maria Grazia Kropp, Alessandro Rambaldi, Giorgio La Nasa, Mario Luppi, Fabio Ciceri, Olimpia Finizio, Adriano Venditti, Francesco Fabbiano, Konstanze Döhner, Michaela Sauer, Arnold Ganser, Sergio Amadori, Franco Mandelli, Hartmut Döhner, Gerhard Ehninger, Richard F. Schlenk, Uwe Platzbecker - New England Journal of Medicine 2013 被引用: 1,606

  5. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Amer M. Zeidan, Lionel Adès, Amit Verma, Michael R. Savona, Abderrahmane Laadem, Aziz Benzohra, Jennie Zhang, Anita Rampersad, Diana Dunshee, Peter G. Linde, Matthew L. Sherman, Rami S. Komrokji, Alan F. List - New England Journal of Medicine 2020 被引用: 537

  6. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

    著者: , , , , , , , , , , , , , , , , , , , , - Blood 2019 被引用: 655

  7. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2023 被引用: 164

  8. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ernst Forjan, Emanuil Gheorghita, Richard Greil, Antónia Hatalova, M Hrubisko, János Jakucs, Polina Kaplan, Sergiy Klymenko, Steffen Koschmieder, Mihaela Lazaroiu, Tamila Lysa, Zvenyslava Masliak, Tamás Masszi, Georgi Mihaylov, Alexander Myasnikov, Uwe Platzbecker, Mathieu Puyade, Jérôme Rey, Lydia Roy, Jiřı́ Schwarz, Aleksander B. Skotnicki, I. Ya. Sokolova, Maria Soroka‐Wojtaszko, Jolanta Starzak-Gwóźdź, Vera Stoeva, Jose Miguel Torregrosa‐Diaz, Anna Vallova, Elena Volodicheva, Krzysztof Warzocha, Ella Willenbacher, Dominik Wolf‎ - The Lancet Haematology 2020 被引用: 347

  9. Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JCO Clinical Cancer Informatics 2023 被引用: 87

  10. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2023 被引用: 132

  11. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

    著者: , , , , , , , , , , , , - The Lancet Haematology 2017 被引用: 315

  12. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Benoit Destenaves, Xiaobin Yuan, Kun Yu, Sara Dar, Lernik Ohanjanian, Keisuke Kuida, Jianjun Xiao, Catherine Scholz, Antonio Gualberto, Uwe Platzbecker - Leukemia 2021 被引用: 178

  13. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Polina Stepensky, Al‐Ola Abdallah, Carlos Fernández de Larrea - Journal of Clinical Oncology 2024 被引用: 83

  14. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christian Thiede - The Lancet Oncology 2018 被引用: 354

  15. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

    著者: , , , , , , , , , , , , , , , , , , - Blood Advances 2022 被引用: 121

  16. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2017 被引用: 376

  17. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Katja Sockel, Malte von Bonin, Carsten Müller‐Tidow, Uwe Platzbecker, Wolfgang E. Berdel, Hubert Serve, Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig, Christian Thiede, for the Study Alliance Leukemia (SAL) - Blood 2021 被引用: 164

  18. Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears

    著者: , , , , , , , , , , , , , , , , - BMC Cancer 2022 被引用: 76

  19. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fabio Ciceri, Jaime Sanz, Ali Bazarbachi, Arnon Nagler, Mohamad Mohty - Bone Marrow Transplantation 2020 被引用: 203

  20. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Binje Vick, Irmela Jeremias, Andreas Trumpp, Jeroen Krijgsveld, Carsten Müller‐Tidow, Sascha Dietrich - Blood 2022 被引用: 102

  21. Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Phillip Scheinberg, Reinhard Stauder, Arjan A. van de Loosdrecht, Andrew H. Wei, Mikkael A. Sekeres, Pierre Fenaux - Blood 2023 被引用: 92

  22. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

    著者: , , , , , , , , , , , - Blood 2002 被引用: 1,729

  23. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

    著者: , , , , , , , , , , , , , , , , , , , , , - Blood 2013 被引用: 667

  24. Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Francesco Passamonti, Fabio Ciceri, Niccolò Bolli, Alessandro Rambaldi, Wolfgang Kern, Shahram Kordasti, Françesc Solé, Laura Palomo, Guillermo Sanz, Armando Santoro, Uwe Platzbecker, Pierre Fenaux, Luciano Milanesi, Torsten Haferlach, Gastone Castellani, Matteo Giovanni Della Porta - Journal of Clinical Oncology 2021 被引用: 225